Asymchem Laboratories (Tianjin) Co., Ltd. (HKG:6821)

Market Cap	50.27B +55.3%
Revenue (ttm)	7.88B +16.6%
Net Income	1.26B +11.7%
EPS	3.53 +10.0%
Shares Out	n/a
PE Ratio	39.83
Forward PE	28.29
Dividend	1.20 (1.28%)
Ex-Dividend Date	Jun 25, 2025

Volume	371,300
Open	90.45
Previous Close	88.85
Day's Range	87.60 - 94.80
52-Week Range	67.15 - 116.60
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About HKG:6821

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in ke...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 10,617
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6821

Financial Performance

In 2025, HKG:6821's revenue was 6.67 billion, an increase of 14.91% compared to the previous year's 5.80 billion. Earnings were 1.13 billion, an increase of 19.35%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error